Biotech faces setbacks after Incyte's experimental cancer drug fails testing - Technical.ly Delaware

Business

Apr. 9, 2018 7:28 am

Biotech faces setbacks after Incyte’s experimental cancer drug fails testing

After a promising start, the Wilmington biotech company announced Friday that its epacadostat trial did not improve patient outcomes.

If this is what you picture when you hear the word "biotech," read on.

(Photo by Flickr user Bill Dickinson, used under a Creative Commons license)

Wilmington-based Incyte’s promising cancer drug, epacadostat, failed in trial that paired it with Merck’s drug Keytruda — a setback for the Wilmington biotech company that caused a dramatic 18 percent drop in its shares Friday.

In a chain reaction, other biotech companies including NewLink Genetics Corp. in Ames, Iowa, and Corvus Pharmaceuticals Inc. in Burlingame, California, also saw their stocks fall.

The Wall Street Journal reported:

Incyte’s drug, epacadostat, was previously viewed as one of the more promising of the next generation of cancer drugs designed to work by harnessing the patients’ own immune systems to destroy tumor cells.

Merck, Bristol-Myers Squibb Co. and other companies sell older types of immunotherapies that have improved treatment for certain cancers including the skin cancer melanoma and lung cancer. The market for these drugs is booming: Merck’s global Keytruda sales more than doubled to $3.8 billion last year.

But they don’t work for every patient, so companies have been racing to test whether combining older immunotherapies with other drugs could further improve patient survival.

Although promising in early trials, it was found in a larger trial launched in 2016 that the combination of epacadostat and Keytruda did not improve outcomes in test patients.

Last summer, an AstraZeneca study testing two PLC immunotherapies for lung cancer failed, calling into question the effectiveness of previously promising combination drug therapy.

Read the full story -30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

These Sussex Tech students are headed to the national Future Health Professionals championships

5 Delaware biotech startups to watch

Christiana Care seeks FDA approval for CRISPR cancer trial

SPONSORED

Delaware

Hear from the privacy pros at Security by the Schuylkill

Philadelphia

Technically Media

Technical.ly Editorial Intern (Summer 2019)

Apply Now
Malvern, PA

Vanguard

Senior Front End Engineer – CX Journey Lab

Apply Now
Philadelphia

Cohere

Digital Marketing Manager

Apply Now

TheraV’s ELIX device for amputees is testing well as the startup plans growth

Delaware Environmental Institute fellow studies wetlands to understand climate change

Meet the UD professor featured in HBO’s ‘The Case Against Adnan Syed’

SPONSORED

Delaware

Learn to lead digital transformation at Phorum 2019

Baltimore, MD 21201

14 West

Senior Software Engineer (Java + Apache Spark)

Apply Now
Radnor, PA

BankMobile

Sr. Automation Engineer

Apply Now

Sign-up for daily news updates from Technical.ly Delaware

Do NOT follow this link or you will be banned from the site!